BioCardia Announces Results From Open Label Roll-In Cohort Of Patients Having Chronic Myocardial Ischemia With Refractory Angina; Showed Avg. Increase In Exercise Tolerance Of 107 Seconds And An Avg. Of 82% Reduction In Angina Episodes At The Primary Six-Month Follow-Up Endpoint
Portfolio Pulse from Benzinga Newsdesk
BioCardia announced results from its open label roll-in cohort study for patients with chronic myocardial ischemia and refractory angina, showing an average increase in exercise tolerance of 107 seconds and an average reduction in angina episodes of 82% at the six-month follow-up.
May 01, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCardia's recent study results indicate significant improvements in treatment outcomes for patients with chronic myocardial ischemia and refractory angina, potentially boosting investor confidence and interest in the company's therapies.
The positive outcome from BioCardia's study is likely to be viewed favorably by investors, as it demonstrates the efficacy of the company's treatment for a chronic condition, potentially leading to increased demand and higher revenues for the company. This could result in a short-term positive impact on BCDA's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100